首页>
外国专利>
PREPARATIONS anticonvulsant and antipsychotic medicines and their use for WEIGHT LOSS CHALLENGE
PREPARATIONS anticonvulsant and antipsychotic medicines and their use for WEIGHT LOSS CHALLENGE
展开▼
机译:抗惊厥药和抗精神病药的制备及其对减肥的挑战
展开▼
页面导航
摘要
著录项
相似文献
摘要
1. the pharmaceutical composition u0434u043bu00a0 u043fu0440u0435u0434u043eu0442u0432u0440u0430u0449u0435u043du0438u00a0 u043fu0440u0438u0431u0430u0432u043bu0435u043du0438u00a0 weight, u0441u0432u00a0u0437u0430u043du043du043eu0433u043e using psychotherapy agent containing the first connection and the second compound, where the first connection u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 psychotherapy agent and a second connection u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u043fu0440u043eu0442u0438u0432u043eu0441u0443u0434u043eu0440u043eu0436u043du044bu043c tool.;2. pharmaceutical composition for 1, in which u0443u043fu043eu043cu00a0u043du0443u0442u044bu0439 u043fu0441u0438u0445u043eu0442u0435u0440u0430u043fu0435u0432u0442u0438u0447u0435u0441u043au0438u0439 agent u0432u044bu0431u0438u0440u0430u0435u0442u0441u00a0 of group u0441u043eu0441u0442u043eu00a0u0449u0435u0439 carbonate u043bu0438u0442u0438u00a0, synthase u043bu0438u0442u0438u00a0, u0432u0430u043bu044cu043fu0440u043eu0430u0442u0430, to u043eu043cu0431u0438u043du0430u0446u0438u0439 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 acceptable salts or u043fu0440u043eu043bu0435u043au0430u0440u0441u0442u0432.;3. pharmaceutical composition for 1, in which u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u043fu0440u043eu0442u0438u0432u043eu0441u0443u0434u043eu0440u043eu0436u043du043eu0435 means u0432u044bu0431u0438u0440u0430u0435u0442u0441u00a0 of group u0441u043eu0441u0442u043eu00a0u0449u0435u0439 of u0442u043eu043fu0438u0440u0430u043cu0430u0442u0430, u0437u043eu043du0438u0437u0430u043cu0438u0434u0430 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 ol u0438u0435u043cu043bu0435u043cu044bu0445 salts or u043fu0440u043eu043bu0435u043au0430u0440u0441u0442u0432, and their combinations.;4. pharmaceutical composition for 1, in which the first connection u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 psychotherapy tool, and a second connection u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0437u043eu043du0438u0437u0430u043cu0438 the house.;5. the pharmaceutical composition according to paragraph 4, in which the first connection u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u043bu0438u0442u0438u00a0 carbonate or u0446u0438u0442u0440u0430u0442u043eu043c u043bu0438u0442u0438u00a0.;6. the pharmaceutical composition according to paragraph 4, in which the first connection u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0432u0430u043bu044cu043fu0440u043eu0430u0442u043eu043c.;7. pharmaceutical composition for u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 1, in which the first connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 salt u043bu0438u0442u0438u00a0 and u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 second connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0437u043eu043du0438u0437u0430u043cu0438u0434u043eu043c.;8. pharmaceutical composition for u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 1, in which the first connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0432u0430u043bu044cu043fu0440u043eu0438u0435u0432u043eu0439 acid or its u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 acceptable salt, complex ether, um u0438u0434u043eu043c or u043fu0440u043eu043bu0435u043au0430u0440u0441u0442u0432u043eu043c and u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 second connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0437u043eu043du0438u0437u0430u043cu0438u0434u043eu043c.;9. pharmaceutical composition for u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 1, in which the first connection and the second connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 u043cu0438u0440u0442u0430u0437u0430u043fu0438u043du043eu043c, u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0437u043eu043du0438u0437u0430u043cu0438u0434u043eu043c.;10. pharmaceutical composition for u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 1, in which the first connection and the second connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 u043cu0438u0440u0442u0430u0437u0430u043fu0438u043du043eu043c, u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0431u0443u043fu0440u043eu043fu0438u043eu043du043eu043c.;11. pharmaceutical composition for u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 1, in which the first connection and the second connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0441u0435u0442u0438u043fu0442u0438u043bu0438u043du043eu043c, u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0437u043eu043du0438u0437u0430u043cu0438u0434u043eu043c.;12. pharmaceutical composition for u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 1, in which the first connection and the second connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0441u0435u0442u0438u043fu0442u0438u043bu0438u043du043eu043c, u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0431u0443u043fu0440u043eu043fu0438u043eu043du043eu043c.;13. pharmaceutical composition for u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 1, in which the first connection and the second connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 u043cu0438u0440u0442u0430u0437u0430u043fu0438u043du043eu043c, u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 combination u0437u043eu043du0438u0437u0430u043cu0438u0434u0430 and boo u043fu0440u043eu043fu0438u043eu043du0430.;14. pharmaceutical composition for u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 1, in which the first connection and the second connection u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0441u0435u0442u0438u043fu0442u0438u043bu0438u043du043eu043c, u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 combination u0437u043eu043du0438u0437u0430u043cu0438u0434u0430 and boo u043fu0440u043eu043fu0438u043eu043du0430.;15. method u043fu0440u0435u0434u043eu0442u0432u0440u0430u0449u0435u043du0438u00a0 u043fu0440u0438u0431u0430u0432u043bu0435u043du0438u00a0 weight, u0441u0432u00a0u0437u0430u043du043du043eu0433u043e using psychotherapy agent, containing a definition of the individual, u043du0443u0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 that at u0439u0441u0442u0432u0438u0438, individual psychotherapy and treatment agent and u043fu0440u043eu0442u0438u0432u043eu0441u0443u0434u043eu0440u043eu0436u043du044bu043c tool.;16. method for u0432u044bu0431u0438u0440u0430u0435u0442u0441u00a0 p.15, which u043fu0441u0438u0445u043eu0442u0435u0440u0430u043fu0435u0432u0442u0438u0447u0435u0441u043au0438u0439 agent from the group u0441u043eu0441u0442u043eu00a0u0449u0435u0439 carbonate u043bu0438u0442u0438u00a0, synthase u043bu0438u0442u0438u00a0, u0432u0430u043bu044cu043fu0440u043eu0430u0442u0430, their combinations and their u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441 kee acceptable salts, complex esters, amides series or u043fu0440u043eu043bu0435u043au0430u0440u0441u0442u0432 and u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u043fu0440u043eu0442u0438u0432u043eu0441u0443u0434u043eu0440u043eu0436u043du043eu0435 means u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0437u043eu043du0438u0437u0430u043cu0438u0434u043eu043c.;17. method for u0432u044bu0431u0438u0440u0430u0435u0442u0441u00a0 p.15, which u043fu0441u0438u0445u043eu0442u0435u0440u0430u043fu0435u0432u0442u0438u0447u0435u0441u043au0438u0439 agent from the group, u0441u043eu0441u0442u043eu00a0u0449u0435u0439 of u043cu0438u0440u0442u0430u0437u0430u043fu0438u043du0430, u0441u0435u0442u0438u043fu0442u0438u043bu0438u043du0430 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 e.p. study are acceptable salts, complex the moat, amides series or u043fu0440u043eu043bu0435u043au0430u0440u0441u0442u0432 and u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u043fu0440u043eu0442u0438u0432u043eu0441u0443u0434u043eu0440u043eu0436u043du043eu0435 means u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0437u043eu043du0438u0437u0430u043cu0438u0434u043eu043c.;18. method u043fu043eu0434u0430u0432u043bu0435u043du0438u00a0 appetite of an individual, containing a definition of the individual, u043du0443u0436u0434u0430u044eu0449u0435u0433u043eu0441u00a0 in this impact, and treatment of the individual, the first connection and the second sock u0434u0438u043du0435u043du0438u0435u043c, where the first connection u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 psychotherapy agent and a second connection u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u043fu0440u043eu0442u0438u0432u043eu0441u0443u0434u043eu0440u043eu0436u043du044bu043c tool.;19. way on p.18, which u043fu0441u0438u0445u043eu0442u0435u0440u0430u043fu0435u0432u0442u0438u0447u0435u0441u043au0438u0439 agent u0432u044bu0431u0438u0440u0430u0435u0442u0441u00a0 of group u0441u043eu0441u0442u043eu00a0u0449u0435u0439 carbonate u043bu0438u0442u0438u00a0, synthase u043bu0438u0442u0438u00a0, u0432u0430u043bu044cu043fu0440u043eu0430u0442u0430 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 acceptable complex salts, esters, amides series or u043fu0440u043eu043bu0435u043au0430u0440u0441u0442u0432 and u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u043fu0440u043eu0442u0438u0432u043eu0441u0443u0434u043eu0440u043eu0436u043du043eu0435 means u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0437u043eu043du0438u0437u0430u043cu0438u0434u043eu043c.;20. way on p.18, which u043fu0441u0438u0445u043eu0442u0435u0440u0430u043fu0435u0432u0442u0438u0447u0435u0441u043au0438u0439 agent u0432u044bu0431u0438u0440u0430u0435u0442u0441u00a0 of group u0441u043eu0441u0442u043eu00a0u0449u0435u0439 of u043cu0438u0440u0442u0430u0437u0430u043fu0438u043du0430, u0441u0435u0442u0438u043fu0442u0438u043bu0438u043du0430 and u0444u0430u0440u043cu0430u0446u0435u0432u0442u0438u0447u0435u0441u043au0438 e.p. study are acceptable salts, complex the moat, amides series or u043fu0440u043eu043bu0435u043au0430u0440u0441u0442u0432 and u0443u043fu043eu043cu00a0u043du0443u0442u043eu0435 u043fu0440u043eu0442u0438u0432u043eu0441u0443u0434u043eu0440u043eu0436u043du043eu0435 means u00a0u0432u043bu00a0u0435u0442u0441u00a0 u0437u043eu043du0438u0437u0430u043cu0438u0434u043eu043c.
展开▼